Therapy Areas
Therapy Areas
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cardiovascular
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.
Alnylam/Roche Score Another Phase II Win With Zilebesiran
Positive topline results from the KARDIA-2 study in hypertension mean there are now two Phase II trials down with one more to go before a planned pivotal cardiovascular outcomes trial.
Bayer Boss Rules Out Divisions Split For Now
CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”
Bayer Bets Big On External Innovation With BridgeBio Acoramidis Pact
The German major's internal R&D fortunes in the cardiovascular space have been mixed, with asundexian faltering in a recent atrial fibrillation trial, so getting hold of the European rights to BridgeBio's recently-filed ATTR-CM therapy is a timely boost.
FDA Delay Will Not Push Rocket Pharma Off Its Trajectory
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.
Therapy Areas
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cardiovascular
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.
Alnylam/Roche Score Another Phase II Win With Zilebesiran
Positive topline results from the KARDIA-2 study in hypertension mean there are now two Phase II trials down with one more to go before a planned pivotal cardiovascular outcomes trial.
Bayer Boss Rules Out Divisions Split For Now
CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”
Bayer Bets Big On External Innovation With BridgeBio Acoramidis Pact
The German major's internal R&D fortunes in the cardiovascular space have been mixed, with asundexian faltering in a recent atrial fibrillation trial, so getting hold of the European rights to BridgeBio's recently-filed ATTR-CM therapy is a timely boost.
FDA Delay Will Not Push Rocket Pharma Off Its Trajectory
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.
Therapy Areas
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cardiovascular
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.
Alnylam/Roche Score Another Phase II Win With Zilebesiran
Positive topline results from the KARDIA-2 study in hypertension mean there are now two Phase II trials down with one more to go before a planned pivotal cardiovascular outcomes trial.
Bayer Boss Rules Out Divisions Split For Now
CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”
Bayer Bets Big On External Innovation With BridgeBio Acoramidis Pact
The German major's internal R&D fortunes in the cardiovascular space have been mixed, with asundexian faltering in a recent atrial fibrillation trial, so getting hold of the European rights to BridgeBio's recently-filed ATTR-CM therapy is a timely boost.
FDA Delay Will Not Push Rocket Pharma Off Its Trajectory
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.
Therapy Areas
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cardiovascular
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.
Alnylam/Roche Score Another Phase II Win With Zilebesiran
Positive topline results from the KARDIA-2 study in hypertension mean there are now two Phase II trials down with one more to go before a planned pivotal cardiovascular outcomes trial.
Bayer Boss Rules Out Divisions Split For Now
CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”
Bayer Bets Big On External Innovation With BridgeBio Acoramidis Pact
The German major's internal R&D fortunes in the cardiovascular space have been mixed, with asundexian faltering in a recent atrial fibrillation trial, so getting hold of the European rights to BridgeBio's recently-filed ATTR-CM therapy is a timely boost.
FDA Delay Will Not Push Rocket Pharma Off Its Trajectory
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.
Therapy Areas
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cardiovascular
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.
Alnylam/Roche Score Another Phase II Win With Zilebesiran
Positive topline results from the KARDIA-2 study in hypertension mean there are now two Phase II trials down with one more to go before a planned pivotal cardiovascular outcomes trial.
Bayer Boss Rules Out Divisions Split For Now
CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”
Bayer Bets Big On External Innovation With BridgeBio Acoramidis Pact
The German major's internal R&D fortunes in the cardiovascular space have been mixed, with asundexian faltering in a recent atrial fibrillation trial, so getting hold of the European rights to BridgeBio's recently-filed ATTR-CM therapy is a timely boost.
FDA Delay Will Not Push Rocket Pharma Off Its Trajectory
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.
Therapy Areas
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cardiovascular
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.
Alnylam/Roche Score Another Phase II Win With Zilebesiran
Positive topline results from the KARDIA-2 study in hypertension mean there are now two Phase II trials down with one more to go before a planned pivotal cardiovascular outcomes trial.
Bayer Boss Rules Out Divisions Split For Now
CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”
Bayer Bets Big On External Innovation With BridgeBio Acoramidis Pact
The German major's internal R&D fortunes in the cardiovascular space have been mixed, with asundexian faltering in a recent atrial fibrillation trial, so getting hold of the European rights to BridgeBio's recently-filed ATTR-CM therapy is a timely boost.
FDA Delay Will Not Push Rocket Pharma Off Its Trajectory
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.
Therapy Areas
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cardiovascular
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.
Alnylam/Roche Score Another Phase II Win With Zilebesiran
Positive topline results from the KARDIA-2 study in hypertension mean there are now two Phase II trials down with one more to go before a planned pivotal cardiovascular outcomes trial.
Bayer Boss Rules Out Divisions Split For Now
CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”
Bayer Bets Big On External Innovation With BridgeBio Acoramidis Pact
The German major's internal R&D fortunes in the cardiovascular space have been mixed, with asundexian faltering in a recent atrial fibrillation trial, so getting hold of the European rights to BridgeBio's recently-filed ATTR-CM therapy is a timely boost.
FDA Delay Will Not Push Rocket Pharma Off Its Trajectory
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.